Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence

BACKGROUND: The use of direct oral anticoagulants (DOACs) is restricted by the limitations of clinical trials guiding therapy for patients with renal impairment, as many of these trials excluded patients with severe renal impairment. There are currently four agents available: dabigatran, rivaroxaban...

Descripción completa

Detalles Bibliográficos
Autores principales: Willett, Kristine C, Morrill, Amanda M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388260/
https://www.ncbi.nlm.nih.gov/pubmed/28435279
http://dx.doi.org/10.2147/TCRM.S88911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388260/
https://www.ncbi.nlm.nih.gov/pubmed/28435279
http://dx.doi.org/10.2147/TCRM.S88911

Ejemplares similares